Brought to you by 
Clinical Genomics completes $26mm second round
04 Jun 2018
Executive Summary
Liquid biopsy developer Clinical Genomics Pty. Ltd. raised $26mm through what is assumed to be its Series B round. New investors Moelis Australia Asset Management and Regal were joined by returning backers Quest Diagnostics and OneVentures. Proceeds will go towards commercialization of the Colvera blood test for early detection of colorectal cancer recurrence, and will also support development of the test as a colorectal cancer screening tool.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clinical Genomics completes $26mm second round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice